Here is a slide from a cellular immunotherapy presentation that highlights just how novel the CDH17 antigen target is….admittedly it’s a few years old but clearly shows that CDH17 is a relatively new target. This effectively means other companies are at least 10 years behind CHM in clinical development process….
Here is a slide from a cellular immunotherapy presentation that...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
-0.001(25.0%) |
Mkt cap ! $9.747M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.3¢ | $11.33K | 3.775M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 75 | 71644408 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 87927011 | 26 |
View Market Depth
| Last trade - 14.48pm 31/07/2025 (20 minute delay) ? |
| CHM (ASX) Chart |